Do You Believe in GeneDx Holdings Corp.’s (WGS) Durable Competitive Moat?

1 hour ago 1

Soumya Eswaran

Mon, May 4, 2026 astatine 9:03 AM CDT 3 min read

Fred Alger Management, an concern absorption company, released its “Alger Small Cap Focus Fund” first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. In the archetypal 4th of 2026, the Class A shares of the Alger Small Cap Fund underperformed the Russell 2000 Growth Index. The Information Technology and Consumer Discretionary sectors contributed to the performance, portion Health Care and Energy detracted from the performance. US equities experienced a volatile play successful the archetypal 4th of 2026, driven by AI disruption and the U.S.-Iran struggle that began successful precocious February. The Fund identifies opportunities successful companies that are adopting and facilitating the exertion arsenic it evolves into an agentic signifier portion navigating AI disruption challenges. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Alger Small Cap Focus Fund highlighted stocks similar GeneDx Holdings Corp. (NASDAQ:WGS). GeneDx Holdings Corp. (NASDAQ:WGS) is simply a genomics institution that offers pediatric and uncommon illness diagnostics services. On May 1, 2026, GeneDx Holdings Corp. (NASDAQ:WGS) closed astatine $65.38 per share. One-month instrumentality of GeneDx Holdings Corp. (NASDAQ:WGS) was -1.85%, and its shares gained 2.46% implicit the past 52 weeks. GeneDx Holdings Corp. (NASDAQ:WGS) has a marketplace capitalization of $1.92 billion.

Alger Small Cap Focus Fund stated the pursuing regarding GeneDx Holdings Corp. (NASDAQ:WGS) successful its Q1 2026 capitalist letter:

"GeneDx Holdings Corp. (NASDAQ:WGS) is simply a specialty genomics laboratory focused connected delivering analyzable familial tests, including full exome and genome sequencing, to diagnose pediatric uncommon diseases. The institution possesses a broad and proprietary database of familial information that enables it to present superior diagnostic yields comparative to competitors and alternate investigating modalities, creating a meaningful competitory vantage successful a highly specialized market. During the quarter, shares detracted from show driven by 2 superior factors. First, portion the institution reported fiscal 4th fourth gross supra expert estimates, the magnitude of the upside was little than investors anticipated arsenic mean selling prices per trial remained dependable connected a sequential basis. Second, the motorboat of a competing genomics assay by a well-known diagnostics adjacent introduced concerns astir imaginable marketplace stock erosion successful the uncommon illness investigating space. Despite these headwinds, we judge GeneDx’s established marketplace entree and the extent of its genomic database correspond a durable competitory moat."

Read Entire Article